Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

Open link

Publication date

May 2021

DOI

10.1038/s41416-021-01312-1

Publisher

Springer Science and Business Media LLC

Abstract

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-

Extracted data

We use cookies to provide a better user experience.

Data Protection

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

Open link

Publication date

May 2021

DOI

10.1038/s41416-021-01312-1

Publisher

Springer Science and Business Media LLC

Abstract

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-

Extracted data

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients:a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)

van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients:a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)

van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Tije, Bert-Jan J Ten
Veldt, Astrid A M van der
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Tije, Bert-Jan J Ten
Veldt, Astrid A M van der
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)

van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)

van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1): First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.

May 2021

Since the publication of this paper, the authors have noticed an error in the Abstract where the val...

Correction:First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction:First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction:First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients:a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)

van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients:a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)

van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Tije, Bert-Jan J Ten
Veldt, Astrid A M van der
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Tije, Bert-Jan J Ten
Veldt, Astrid A M van der
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)

van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)

van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-

van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.

May 2021

Since the publication of this paper, the authors have noticed an error in the Abstract where the val...

Correction:First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction:First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction:First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S
Suijkerbuijk, Karijn P M
Blokx, Willeke A M
Ten Tije, Bert-Jan J
van der Veldt, Astrid A M
Vreugdenhil, Art
Boers-Sonderen, Marye J
van den Eertwegh, Alfonsus J M

May 2021

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients:a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)

van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients:a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)

van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.

May 2022

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1</p

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Abstract

Extracted data

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Abstract

Extracted data

Related items

Related items